No advantage of Sodium Bicarbonate and Acetyl cysteine in Preventing Contrast Nephropathy

Steven D. Weisbord et al in NEJM published the results of Prevention of Serious Adverse Events Following Angiography (PRESERVE) trial which was done compare intravenous sodium bicarbonate with intravenous sodium chloride and oral acetylcysteine with oral placebo for the prevention of major adverse outcomes and acute kidney injury in a large population of high-risk patients undergoing coronary or noncoronary angiography.

Among patients at high risk for renal complications who were undergoing angiography, there was no benefit of intravenous sodium bicarbonate over intravenous sodium chloride or of oral acetylcysteine over placebo for the prevention of death, need for dialysis, or persistent decline in kidney function at 90 days or for the prevention of contrast-associated acute kidney injury. 

Reference and Further Reading 

• Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. The article was published on November 12, 2017, at NEJM.org.DOI:10.1056/NEJMoa1710933

Famous Radiology Blog http://ift.tt/1MM2hKr TeleRad Providers at http://ift.tt/1NgppuI Mail us at sales@teleradproviders.com

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2zteWNS
via IFTTT